Epioxa significantly slows keratoconus progression over 12 months

Epioxa, an epithelium-on corneal collagen cross-linking therapy, made a significant and clinically meaningful difference in keratoconus progression over 12 months, according to a study published in Ophthalmology and Therapy. The procedure, available in the U.S. since March, was approved by the FDA in 2025. Previously, cross-linking for keratoconus required debridement of the corneal epithelium,

Raccontata dahealio.com